Table 4.
Summary of the current literature after treatment of hip cartilage defects with ACI/MACI.
| Author | Design | Procedure | Patients (male/female) | Mean age (range) | Follow-up (months) | Score improvement (pre-post) | Defect size (cm2) | Localization | Grade | Additional treatment |
|---|---|---|---|---|---|---|---|---|---|---|
| Fontana et al. [15] | Retrospective study | ACI, Polymer-based scaffold BioSeed-C (BioTissue Technologies GmbH) | 15 (9/6) | 40.7 (22–52) | 73.8 (72–76) | HHS 39.4 | 2.6 | A (n = 15) FH (n = 3) | Outerbridge 3–4 | Not mentioned |
| Fickert et al. [14] | Case series | MACI, Chondrosphere (CO.DON®) | 6 (5/1) | 33 (25–45) | 11.2 | mHHS 23.5 NAHS 28.1 | 3.6 | A (n = 5) FH (n = 1) | ICRS IIIA–IIB | LR 3 LPR 2 |
| Körsmeier et al. [16] | Case series | MACI, Chondrosphere (CO.DON®) | 16 (14/2) | 31.8 (20–47) | 16.1 (10–29) | NAHS 26 WOMAC 33 | 4.5 | A (n = 16) | Outerbridge 3–4 | LR 2 LPR 4 |
| Schroeder et al. [17] | Case series | MACI, Chondrosphere (CO.DON®) | 20 (16/4) | 33 (22–49) | 12.1 (6–24) | mHHS 30 iHOT33 35% SHV 22% | 5.1 | A (n = 20) | Full-thickness defects | LR 18 |
| Fontana and de Girolamo [33] | Case series | ACI, Polymer-based scaffold BioSeed®-C (BioTissue Technologies GmbH) vs. AMIC Chondro-Gide®, (Geistlich Pharma AG, Switzerland) | ACT 26 (12/14) AMIC 31 (13/18) | ACT 36 ± 9.3 AMIC 36.4 ± 10.3 | 60 | ACT mHHS 37.8 ± 5.9 AMIC mHHS 39.1 ± 5.9 | ACT 2.8 ± 0.7 AMIC 2.9 ± 0.8 | ACT A (n = 26) AMIC A (n = 31) | Outerbridge 3–4 | Not mentioned |
LR = Labrum Repair; LPR = Partial Resection Labrum; A = Acetabulum; FH = Femoral Head.